JP2017113019A5 - - Google Patents

Download PDF

Info

Publication number
JP2017113019A5
JP2017113019A5 JP2017027825A JP2017027825A JP2017113019A5 JP 2017113019 A5 JP2017113019 A5 JP 2017113019A5 JP 2017027825 A JP2017027825 A JP 2017027825A JP 2017027825 A JP2017027825 A JP 2017027825A JP 2017113019 A5 JP2017113019 A5 JP 2017113019A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017027825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017113019A (ja
JP6363747B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017113019A publication Critical patent/JP2017113019A/ja
Publication of JP2017113019A5 publication Critical patent/JP2017113019A5/ja
Application granted granted Critical
Publication of JP6363747B2 publication Critical patent/JP6363747B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017027825A 2011-04-01 2017-02-17 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体 Expired - Fee Related JP6363747B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
US61/471,101 2011-04-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014502846A Division JP6170903B2 (ja) 2011-04-01 2012-03-30 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018122610A Division JP2018172411A (ja) 2011-04-01 2018-06-28 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2017113019A JP2017113019A (ja) 2017-06-29
JP2017113019A5 true JP2017113019A5 (enExample) 2017-10-19
JP6363747B2 JP6363747B2 (ja) 2018-07-25

Family

ID=46932389

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014502846A Expired - Fee Related JP6170903B2 (ja) 2011-04-01 2012-03-30 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2017027825A Expired - Fee Related JP6363747B2 (ja) 2011-04-01 2017-02-17 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2018122610A Pending JP2018172411A (ja) 2011-04-01 2018-06-28 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2020176145A Withdrawn JP2021019619A (ja) 2011-04-01 2020-10-20 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014502846A Expired - Fee Related JP6170903B2 (ja) 2011-04-01 2012-03-30 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018122610A Pending JP2018172411A (ja) 2011-04-01 2018-06-28 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2020176145A Withdrawn JP2021019619A (ja) 2011-04-01 2020-10-20 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Country Status (37)

Country Link
US (5) US20140294832A1 (enExample)
EP (1) EP2694544B1 (enExample)
JP (4) JP6170903B2 (enExample)
KR (2) KR20190079698A (enExample)
CN (2) CN103797030B (enExample)
AU (3) AU2012236296A1 (enExample)
BR (1) BR112013025376A2 (enExample)
CA (2) CA3068997A1 (enExample)
CL (1) CL2013002811A1 (enExample)
CO (1) CO6890074A2 (enExample)
CR (1) CR20130499A (enExample)
CU (1) CU20130128A7 (enExample)
CY (1) CY1121538T1 (enExample)
DK (1) DK2694544T3 (enExample)
DO (1) DOP2013000218A (enExample)
EA (2) EA201991704A3 (enExample)
EC (1) ECSP13012913A (enExample)
ES (1) ES2722824T3 (enExample)
GT (1) GT201300229A (enExample)
HK (1) HK1243426A1 (enExample)
HR (1) HRP20190467T1 (enExample)
HU (1) HUE042706T2 (enExample)
IL (4) IL228633B (enExample)
LT (1) LT2694544T (enExample)
MX (1) MX2013011218A (enExample)
MY (2) MY190951A (enExample)
PE (1) PE20141149A1 (enExample)
PH (4) PH12013502039B1 (enExample)
PL (1) PL2694544T3 (enExample)
PT (1) PT2694544T (enExample)
RS (1) RS58633B1 (enExample)
SG (2) SG193594A1 (enExample)
SI (1) SI2694544T1 (enExample)
TR (1) TR201905101T4 (enExample)
UA (1) UA113623C2 (enExample)
WO (1) WO2012135671A2 (enExample)
ZA (1) ZA201308169B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348462B (zh) 2008-12-19 2015-06-17 巴克斯特国际公司 Tfpi抑制剂和使用方法
BRPI0924058B1 (pt) 2008-12-22 2021-08-17 Novo Nordisk A/S Anticorpos monoclonais, seus usos, bem como composição farmacêutica
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
KR20190079698A (ko) * 2011-04-01 2019-07-05 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (tfpi)에 대한 모노클로날 항체
ES2733958T3 (es) 2012-03-21 2019-12-03 Baxalta GmbH Inhibidores de TFPI y métodos de uso
SG11201406129QA (en) * 2012-03-30 2014-10-30 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
ES2657304T3 (es) 2013-03-15 2018-03-02 Bayer Healthcare Llc Variantes de anticuerpo anti TFPI con unión diferencial a lo largo del intervalo de pH para mejorar la farmacocinética
ES2926773T3 (es) * 2013-03-15 2022-10-28 Novo Nordisk As Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
EP3022228B1 (en) * 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
ES2905085T3 (es) * 2014-09-17 2022-04-07 Novo Nordisk As Anticuerpos que pueden unirse a dos epítopos en el inhibidor de la vía del factor tisular (1-161)
EP3262075B1 (en) * 2015-02-25 2024-03-13 Mogam Institute For Biomedical Research Novel antibody binding to tfpi and composition comprising the same
RU2705540C2 (ru) * 2015-08-19 2019-11-07 Пфайзер Инк. Антитела против ингибитора пути тканевого фактора и их применения
CN112424593A (zh) * 2018-07-25 2021-02-26 索尼公司 凝血系统分析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
BRPI0924058B1 (pt) * 2008-12-22 2021-08-17 Novo Nordisk A/S Anticorpos monoclonais, seus usos, bem como composição farmacêutica
PT3345615T (pt) * 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
KR20190079698A (ko) * 2011-04-01 2019-07-05 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (tfpi)에 대한 모노클로날 항체
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Similar Documents

Publication Publication Date Title
JP2017113019A5 (enExample)
JP2017500018A5 (enExample)
JP2020500538A5 (enExample)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2014221758A5 (enExample)
JP2019535763A5 (enExample)
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
JP2018501197A5 (enExample)
JP2016020389A5 (enExample)
JP2015503909A5 (enExample)
JP2016529229A5 (enExample)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2020536109A5 (enExample)
JP2017533694A5 (enExample)
JP2018535650A5 (enExample)
JP2010521147A5 (enExample)
JP2017501129A5 (enExample)
JP2016519650A5 (enExample)
JP2019505527A5 (enExample)
JP2011157378A5 (enExample)
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
JP2015529641A5 (enExample)
JP2019510739A5 (enExample)
JP2020521478A5 (enExample)